OSE Immuno

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

20 فبراير 2025 11:05:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy

29 يناير 2025 11:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

28 يناير 2025 00:30:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

13 يناير 2025 11:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

11 ديسمبر 2024 11:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Strengthens Leadership and Executive Committee

02 ديسمبر 2024 11:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

04 نوفمبر 2024 00:30:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index

17 أكتوبر 2024 11:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

26 سبتمبر 2024 11:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer

10 سبتمبر 2024 00:30:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis

24 يوليو 2024 01:55:00 بحسب Nasdaq GlobeNewswire

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

03 يوليو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’

01 يوليو 2024 00:30:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

24 يونيو 2024 00:30:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)

20 يونيو 2024 00:30:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth

19 يونيو 2024 11:15:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse

12 يونيو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

05 يونيو 2024 00:30:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Provides Business and Corporate Update

30 مايو 2024 11:15:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

22 مايو 2024 00:30:00 بحسب Nasdaq GlobeNewswire